FrancophonIA/ELRC3.0 huggingface dataset:
English: During their January 2007 meeting, the CHMP, in the light of the overall data submitted and the scientific discussion within the Committee, was of the opinion that the benefit/risk ratio is favourable for Ciprofloxacin Hikma and associated names, that the objections raised should not prevent the granting of a Marketing Authorisation and that the Summary of Product Characteristics, labelling and package leaflet of the Reference Member State should be amended.
Estonian: 2007. aasta jaanuari koosolekul leidis inimtervishoius kasutatavate ravimite komitee, tuginedes kõigile esitatud andmetele ja komiteesisesele teaduslikule arutelule, et Ciprofloxacin Hikma ja sarnaste nimetuste kasulikkuse ja riski suhe on soodne, et tõstatatud küsimused ei saa olla müügiloa andmisel takistuseks ning et viiteliikmesriigi esitatud ravimi omaduste kokkuvõtet, märgistust ja pakendi infolehte tuleb muuta.
English: submitted applications for mutual recognition of Ciprofloxacin Hikma and associated names, 2 mg/ml solution for infusion on the basis of the marketing authorisation granted by the Netherlands on 12 April 2005.
Estonian: esitas taotluse Ciprofloxacin Hikma ja sarnaste nimetuste 2 mg/ml infusioonilahuse vastastikuseks tunnustamiseks Madalmaade poolt 12. aprillil 2005 antud müügiloa alusel.
English: COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) OPINION FOLLOWING AN ARTICLE 29(4)1 REFERRAL FOR Ciprofloxacin Hikma and associated names International Non-Proprietary Name (INN): Ciprofloxacin BACKGROUND INFORMATION Ciprofloxacin Hikma and associated names, 2 mg/ml solution for infusion, is an antibiotic belonging to the quinolone family, effective in vitro against a large number of Gram-negative aerobic bacteria as well as against some Gram-positive organisms.
Estonian: Ciprofloxacin Hikma ja sarnased nimetused, 2 mg/ml infusioonilahus, on antibiootikum, mis kuulub kinoloonide rühma, mis on in vitro tõhus paljude gramnegatiivsete aeroobsete bakterite ja mõnede grampositiivsete organismide vastu.
English: Other information about Januvia
Estonian: Muu teave Januvia kohta
English: The European Commission granted a marketing authorisation valid throughout the European Union for Januvia on 21 March 2007.
Estonian: Euroopa Komisjon andis Januvia müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 21. märtsil
English: Januvia is taken at a dose of 100 mg once a day.
Estonian: Januviat võetakse annuses 100 mg üks kord ööpäevas.
English: The full EPAR for Januvia can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Januvia kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: • two studies compared Januvia with other antidiabetes medicines.
Estonian: • Kahes uuringus võrreldi Januviat teiste diabeediravimitega.
English: The CHMP decided that Januvia's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee järeldas, et Januvia kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: For more information about treatment with Januvia, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Januviaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: What is Januvia?
Estonian: Mis on Januvia?
English: Serious side effects reported with Januvia include pancreatitis (inflammation of the pancreas) and hypersensitivity (allergic reactions).
Estonian: Januvia kohta teatatud rasked kõrvalnähud on muu hulgas pankreatiit (kõhunäärmepõletik) ja ülitundlikkus (allergilised reaktsioonid).
English: This is a summary of the European public assessment report (EPAR) for Januvia.
Estonian: See on ravimi Januvia Euroopa avaliku hindamisaruande kokkuvõte.
English: Januvia must not be used in people who are hypersensitive (allergic) to sitagliptin or any of the other ingredients.
Estonian: Januviat ei tohi kasutada patsiendid, kes on sitagliptiini või selle ravimi mis tahes muu koostisaine suhtes ülitundlikud (allergilised).
English: What is the risk associated with Januvia?
Estonian: Mis riskid Januviaga kaasnevad?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Januvia.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: If Januvia is taken with a sulphonylurea or insulin, the dose of the sulphonylurea or insulin may need to be lowered to reduce the risk of hypoglycaemia (low blood sugar levels).
Estonian: Kui Januviat võetakse koos sulfonüüluurearavimi või insuliiniga, võib olla vaja vähendada sulfonüüluurearavimi või insuliini annust, et vähendada hüpoglükeemia (vere glükoosivaegus) riski.
English: Januvia was studied in nine studies involving almost 6,000 patients with type 2 diabetes whose blood glucose levels were not adequately controlled:
Estonian: Januviat uuriti üheksas uuringus, milles osales ligikaudu 6000 patsienti, kellel oli II tüüpi diabeet ja kelle organism ei reguleerinud vere glükoosisisaldust rahuldavalt.
English: Januvia is a medicine that contains the active substance sitagliptin.
Estonian: Januvia on ravim, mille toimeaine on sitagliptiin.
English: Why has Januvia been approved?
Estonian: Miks Januvia heaks kiideti?
English: In patients with moderately or severely reduced kidney function the dose of Januvia should be reduced.
Estonian: Keskmise või raske neerupuudulikkusega patsientidel tuleb Januvia annust vähendada.
English: For the full list of all side effects reported with Januvia, see the package leaflet.
Estonian: Januvia kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: When taken on their own, Januvia and metformin produced similar reductions in HbA1c levels, but the effectiveness of Januvia seemed to be slightly lower than that of metformin.
Estonian: Januvia ja metformiin kasutatuna ainsa ravimina vähendasid sarnasel määral HbA1c-sisaldust, kuid Januvia efektiivsus näis olevat veidi väiksem kui metformiini efektiivsus.
English: • three additional studies compared Januvia with placebo when they were added to other antidiabetes medicines: glimepiride (another sulphonylurea), with or without metformin, in 441 patients; the combination of metformin and rosiglitazone (a PPAR-gamma agonist) in 278 patients; and a stable dose of insulin, with or without metformin, in 641 patients.
Estonian: • Kolmes täiendavas uuringus võrreldi Januviat ja platseebot järgmistele diabeediravimitele lisamisel: glimepiriid (teatud sulfonüüluurearavim), koos metformiiniga või ilma, 441 patsiendil; metformiini ja rosiglitasooni (PPARγ agonist) kombinatsioon 278 patsiendil; insuliini püsiv annus koos metformiiniga või ilma 641 patsiendil.
English: In the studies comparing Januvia with other medicines, the effectiveness of adding Januvia to metformin was similar to that of adding glipizide.
Estonian: Uuringutes, kus Januviat võrreldi muude ravimitega, sarnanes metformiinile lisatud Januvia efektiivsus glipsiidile lisatud Januvia efektiivsusega.
English: The active substance in Januvia, sitagliptin, is a dipeptidyl-peptidase-4 (DPP-4) inhibitor.
Estonian: Januvia toimeaine sitagliptiin on ensüümi dipeptidüülpeptidaas-4 (DPP-4) inhibiitor, mis blokeerib inkretiinhormoonide lagunemise organismis.
English: Januvia is used in patients with type 2 diabetes to improve the control of blood glucose (sugar) levels.
Estonian: Januviat kasutatakse II tüüpi diabeediga (suhkurtõvega) patsientide raviks, et parandada vere glükoosisisalduse reguleeritavust organismis.
English: Januvia was more effective than placebo when it was taken alone or in combination with other antidiabetes medicines.
Estonian: Januvia oli kasutamisel ainsa ravimina või koos teiste diabeediravimitega efektiivsem kui platseebo.
English: Hypoglycaemia has been reported in combination with a sulphonylurea in 4.7-13.8% of patients and with insulin in 9.6% of patients.
Estonian: Nende patsientide osakaal, kellel on teatatud hüpoglükeemia esinemisest, on Januviat koos sulfonüüluurearavimiga kasutanute seas 4,7-13,8% ja Januviat koos insuliiniga kasutanute seas 9,6%.
English: In patients taking Januvia on its own, HbA1c levels fell from around 8.0% at the start of the studies by 0.48% after 18 weeks and 0.61% after 24 weeks.
Estonian: Januviat ainsa ravimina kasutanud patsientidel vähenes HbA1c-sisaldus väärtuselt ligikaudu 8,0% uuringu alguses 18 nädala järel 0,48% võrra ja 24 nädala järel 0,61% võrra.
English: How does Januvia work?
Estonian: Kuidas Januvia toimib?
English: What benefit has Januvia shown during the studies?
Estonian: Milles seisneb uuringute põhjal Januvia kasulikkus?
English: In the additional studies, adding Januvia to glimepiride (with or without metformin) led to a reduction in HbA1c levels of 0.45% after 24 weeks, compared with an increase of 0.28% in the patients adding placebo.
Estonian: Täiendavates uuringutes, kus Januviat lisati glimepiriidile (koos metformiiniga või ilma) vähenes 24 nädala järel glükohemoglobiini sisaldus 0,45% võrra, platseebo lisamisel suurenes selle sisaldus 0,28% võrra.
English: How has Januvia been studied?
Estonian: Kuidas Januviat uuriti?
English: How is Januvia used?
Estonian: Kuidas Januviat kasutatakse?
English: What is Januvia used for?
Estonian: Milleks Januviat kasutatakse?
English: • in combination with metformin or a PPAR-gamma agonist (a type of antidiabetes medicine) such as a thiazolidinedione, in patients who are not satisfactorily controlled on metformin or the PPARgamma agonist used on its own;
Estonian: • koos metformiini või PPARγ agonistiga, nt tiasolidiindioonravimiga (samuti diabeediravim), neil patsientidel, kelle vere glükoosisisaldust ainult metformiini ja PPARγ agonistiga rahuldavalt reguleerida ei saa;
English: Januvia or placebo were used on their own in two studies involving 1,262 patients, as an add-on to metformin in one study involving 701 patients, and as an add-on to pioglitazone (a PPAR-gamma agonist) in one study involving 353 patients;
Estonian: • Neljas uuringus võrreldi Januviat platseeboga (näiv ravim): neist kahes (1262 patsienti) vaadeldi Januvia või platseebo kasutamist ainsa ravimina, kolmandas (701 patsienti) lisati kumbagi metformiinile ja neljandas (353 patsienti) lisati kumbagi PPARγ agonistile pioglitasoonile.
English: Adding Januvia to metformin reduced HbA1c levels by 0.67% after 24 weeks, compared with a fall of 0.02% in the patients adding placebo.
Estonian: Januvia lisamisel metformiinile vähenes 24 nädala järel HbA1c-sisaldus veres 0,67% võrra, platseebo korral vähenes 0,02% võrra.
English: HbA1c levels were reduced by 1.03% after 18 weeks in patients adding Januvia to metformin and rosiglitazone, compared with a fall of 0.31% in those adding placebo.
Estonian: Januvia lisamisel metformiinile ja rosiglitasoonile vähenes 18 nädala järel HbA1c-sisaldus veres 1,03% võrra ja platseebo lisamisel vähenes sisaldus 0,31% võrra.
English: One study compared Januvia with glipizide (a sulphonylurea), when they were used as an add-on to metformin in 1,172 patients.
Estonian: Ühes uuringus (1172 patsienti) võrreldi Januviat glipisiidiga (teatud sulfonüüluurearavim) kummagi lisamisel metformiinile.
English: The other study compared Januvia with metformin, used on their own, in 1,058 patients;
Estonian: Teises uuringus (1058 patsienti) võrreldi Januvia ja metformiini kasutamist ainsa ravimina.
English: When added to pioglitazone, Januvia reduced HbA1c levels by 0.85% after 24 weeks, compared with a fall of 0.15% in the patients adding placebo.
Estonian: Januvia lisamisel pioglitasoonile vähenes 24 nädala järel HbA1c-sisaldus veres 0,85% võrra, platseebo korral vähenes 0,15% võrra.
English: Finally, they were reduced by 0.59% in patients adding Januvia to insulin (with or without metformin), compared with a fall of 0.03% in those adding placebo.
Estonian: Januvia lisamisel insuliinile (koos metformiiniga või ilma) vähenes HbA1c-sisaldus veres 0,59% võrra, platseebo lisamisel vähenes sisaldus 0,03% võrra.
English: Two of these studies included children.
Estonian: Neist kahes uuringus osalesid ka lapsed.
English: Opatanol can be used for up to four months, if needed.
Estonian: Opatanoli tohib kasutada vajaduse korral kuni neli kuud.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Opatanol on 17 May 2002.
Estonian: Euroopa Komisjon andis Opatanoli müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 17. mail 2002.
English: Opatanol has been studied in 688 patients in four main studies lasting between six and 14 weeks.
Estonian: Opatanoli kasutamist uuriti 688 patsiendil neljas põhiuuringus, mis kestsid 6-14 nädalat.
English: The full EPAR for Opatanol can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Opatanoli kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Opatanol olopatadine
Estonian: Opatanol olopatadiin
English: Opatanol is used in adults and children aged three years and older.
Estonian: Opatanoli kasutatakse täiskasvanutel ja vähemalt 3-aastastel lastel.
English: If another eye treatment is also being used, there should be a gap of five minutes between treatments; eye ointments should be administered last.
Estonian: Kui samal ajal kasutatakse ka muid ravimeid, peab ravimite manustamisel jätma 5-minutilise vaheaja; silmasalvid tuleb manustada viimasena.
English: When compared with placebo, Opatanol was more effective only when pollen counts were taken into account, showing that the higher the level of pollen in the air, the greater the difference between the effects of Opatanol and those of placebo.
Estonian: Platseeboga võrreldes oli Opatanol efektiivsem ainult õhu õietolmu sisalduse arvestamisel, kusjuures ilmnes, et mida rohkem on õhus õietolmu, seda suurem on Opatanoli ja platseebo toime erinevus.
English: It is given as one drop into the affected eye(s) twice a day, given eight hours apart.
Estonian: Seda manustatakse haigestunud silma (silmadesse) üks tilk kaks korda ööpäevas, 8-tunnise vahega.
English: Other information about Opatanol
Estonian: Muu teave Opatanoli kohta
English: The most common side effects with Opatanol (seen in between 1 and 10 patients in 100) are headache, dysgeusia (taste disturbances), eye pain, eye irritation, dry eyes, abnormal sensations in the eye, dry nose and fatigue (tiredness).
Estonian: Opatanoli kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on peavalu, düsgeusia (maitsehäired), silmavalu, silmaärritus, vääraistingud silmas, ninakuivus ja väsimus.
English: Opatanol was as effective as cromolyn sodium and as levocabastine.
Estonian: Opatanol oli sama efektiivne kui naatriumkromolüün ja levokabastiin.
English: When the receptors are blocked, histamine cannot have its effect, and this leads to a decrease in the symptoms of allergy.
Estonian: Kui retseptorid on blokeeritud, ei saa histamiin mõjuda, mille tõttu allergiasümptomid leevenduvad.
English: Therefore care should be taken by people who wear soft contact lenses.
Estonian: Pehmeid kontaktläätsi kandvad patsiendid peavad seetõttu olema ettevaatlikud.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Opatanol.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For more information about treatment with Opatanol, read the package leaflet (also part of the EPAR) or contact your doctor of pharmacist.
Estonian: Kui vajate Opatanoliga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: This is a summary of the European public assessment report (EPAR) for Opatanol.
Estonian: See on ravimi Opatanol Euroopa avaliku hindamisaruande kokkuvõte.
English: Opatanol was compared with cromolyn sodium (another anti-allergy medicine), with levocabastine (another antihistamine) and, in two studies, with placebo (a dummy treatment).
Estonian: Opatanoli võrreldi naatriumkromolüüniga (samuti allergiaravim), levokabastiiniga (samuti antihistamiin) ja kahes uuringus platseeboga (näiv ravim).
English: What is the risk associated with Opatanol?
Estonian: Mis riskid Opatanoliga kaasnevad?
English: The CHMP decided that Opatanol's benefits are greater than its risks for the treatment of ocular signs and symptoms of seasonal allergic conjunctivitis and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Opatanoli kasulikkus hooajalise allergilise konjunktiviidi silmasümptomite ja -nähtude ravis on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: These include itching, redness and swelling.
Estonian: Need sümptomid on kihelus, punetus ja turse.
English: Olopatadine works by blocking the receptors on which histamine, a substance in the body that causes allergic symptoms, normally attaches itself.
Estonian: Olopatadiini toime seisneb nende retseptorite blokeerimises, mille külge histamiin - allergiasümptomeid põhjustav aine organismis - tavaliselt kinnitub.
English: What is Opatanol?
Estonian: Mis on Opatanol?
English: Why has Opatanol been approved?
Estonian: Miks Opatanol heaks kiideti?
English: Opatanol is a clear eye drop solution, which contains the active substance olopatadine.
Estonian: Opatanol on selge silmatilgalahus, mis sisaldab toimeainena olopatadiini.
English: Opatanol is used to treat the eye symptoms of seasonal allergic conjunctivitis (inflammation of the eyes caused by pollen in patients with hayfever).
Estonian: Optanoli kasutatakse hooajalise allergilise konjunktiviidi (heinanohuga patsientidel õietolmust põhjustatud silmapõletik) silmasümptomite raviks.
English: Opatanol contains benzalkonium chloride, which is known to discolour soft contact lenses.
Estonian: Opatanol sisaldab bensalkooniumkloriidi, mis muudab pehmete kontaktläätsede värvust.
English: For the full list of all side effects reported with Opatanol, see the Package Leaflet.
Estonian: Opatanoli kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: The active substance in Opatanol, olopatadine, is an antihistamine.
Estonian: Opatanoli toimeaine olopatadiin on antihistamiin.
English: At lower pollen counts, there were no differences between the two treatments.
Estonian: Kui õhus sisaldus õietolmu vähe, erinevused puudusid.
English: How is Opatanol used?
Estonian: Kuidas Opatanoli kasutatakse?
English: How does Opatanol work?
Estonian: Kuidas Opatanol toimib?
English: What benefit has Opatanol shown during the studies?
Estonian: Milles seisneb uuringute põhjal Opatanoli kasulikkus?
English: What is Opatanol used for?
Estonian: Milleks Opatanoli kasutatakse?
English: In all of the studies, the main measure of effectiveness was based on the degree of itching and redness in the eye. One of the placebo studies also looked at these symptoms in relation to pollen counts.
Estonian: Efektiivsuse põhinäitaja kõikides uuringutes oli silmade kiheluse ja punetuse aste.
English: How has Opatanol been studied?
Estonian: Kuidas Opatanoli uuriti?
English: The medicine can only be obtained with a prescription.
Estonian: Opatanol on retseptiravim.
English: - Try to take your tablet at the same time each day.
Estonian: - Püüdke tabletti võtta iga päev samal ajal.
English: 51689 Reims Cedex France
Estonian: 51689 Reims Cedex Prantsusmaa
English: Keep your tablets in a safe place where children cannot see or reach them.
Estonian: Hoidke tablette turvalises kohas, kus lapsed neid ei näe ega ulatu nendeni.
English: It is a long-term treatment and you may need to take it for several years.
Estonian: See on pikaajaline ravi ning tihti kasutatakse seda mitmed aastad.
English: After the Commission Decision the Member State Competent Authorities, in liaison with the Reference Member State, will update the product information as required.
Estonian: Pärast Komisjoni otsust ajakohastavad liikmesriikide vastavad ametkonnad, olles ühenduses referentsliikmesriigiga, tooteinformatsiooni vastavalt nõuetele.
English: If bleeding persists, further evaluation should be considered.
Estonian: Kui verejooks kestab, tuleks kaaluda täiendavate uuringute läbiviimist.
English: Number (%) of patients who had died.
Estonian: e Patsientide arv (%), kes sel ajavahemikul surid.
English: Your tablets could harm them.
Estonian: Teie tabletid võivad lapsi kahjustada.
English: Detailed information on this medicine is available on the web site of {MA/Agency}
Estonian: Täpne informatsioon selle ravimi kohta on kättesaadav {Liikmesriik/Amet} kodulehel
English: All patients received treatment with vitamin D and calcium.
Estonian: Kõik patsiendid said D-vitamiini ja kaltsiumipreparaati.
English: - The usual dose is one tablet once a day.
Estonian: - Tavaline annus on üks tablett üks kord ööpäevas.
English: You should talk to your doctor about the risks and treatment options.
Estonian: Palun rääkige arstiga riskidest ja ravivõimalustest.
English: There is no specific antidote to overdose and treatment must be symptomatic.
Estonian: Üleannusel puudub spetsiifiline antidoot ja ravi peab olema sümptomaatiline.
English: This would be seen in a blood test.
Estonian: Seda saab määrata vereanalüüsil;
English: Thirteen out of the 14 patients enrolled completed 12 months of combination treatment (one patient was lost to follow-up).
Estonian: Kolmteist patsienti 14-st lõpetasid 12kuulise kombineeritud ravikuuri (üks patsient ei ilmunud järelkontrolli).
English: Like all medicines, Arimidex can cause side effects, although not everybody gets them.
Estonian: Nagu kõik ravimid, võib ka Arimidex põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
English: The rate of prolonged (more than 24 weeks) stable disease, the rate of progression, and survival were also calculated.
Estonian: Arvutati ka pikenenud (enam kui 24 nädalat) stabiilse haiguse tase, progresseerumise tase ja elulemus.
English: Your bones may be less strong and may be more likely to fracture.
Estonian: Teie luud võivad muutuda hapramaks ning luumurde võib rohkem tekkida.
English: This may lower the mineral content of your bones.
Estonian: See võib vähendada teie luude mineraalisisaldust.
English: This belongs to a group of medicines called ‘aromatase inhibitors'.
Estonian: See kuulub ravimite rühma, mida nimetatakse aromataasi inhibiitoriteks.
English: Anastrozole inhibits CYPs 1A2, 2C8/9 and 3A4 in vitro.
Estonian: Anastrosool pärsib CYP 1A2, 2C8/9 ja 3A4 in vitro keskkonnas.
English: Measured mean plasma concentrations were 44.4 (±14.7) ng/ml and 165 (±90) ng/ml respectively.
Estonian: Mõõdetud keskmisteks plasma kontsentratsioonideks olid vastavalt 44,4 (±14,7) ng/ml ja 165 (±90) ng/ml.
English: Important information about some of the ingredients of Arimidex Arimidex contains lactose which is a type of sugar.
Estonian: Oluline teave Arimidexi mõnede koostisainete kohta Arimidex sisaldab laktoosi, mis on teatud tüüpi suhkur.
English: The reduction was transient as all mating and fertility parameters were similar to control group values following a 9 week treatment-free recovery period.
Estonian: Vähenemine oli ajutine, kuna kõik paaritumisvõime ja fertiilsuse parameetrid sarnanesid vastavate kontrollrühma parameetritega pärast 9-nädalast ravivaba taastusperioodi.
English: Do not use Arimidex after the expiry date which is stated on the carton and <container> [To be completed nationally].
Estonian: Ärge kasutage Arimidexi pärast kõlblikkusaega, mis on märgitud karbil ja <pakendil> [Täidetakse riiklikult].